Analyst: This Penny Stock Could Triple

PSTI stock hasn't touched $4.50 since 2014

Jul 31, 2018 at 2:15 PM
facebook twitter linkedin


B. Riley/FBR initiated coverage on Pluristem Therapeutics Inc. (NASDAQ:PSTI) with a "buy" rating and $4.50 price target -- a roughly 266% premium to last night's close. The analyst in coverage cited optimism surrounding the company's cell therapy treatments.

The bullish note has failed to spark a meaningful move higher in PSTI stock, though, which was last seen up 1% at $1.24. Longer term, the penny stock has been in a channel of lower highs and lows since topping out at an annual high of $2.12 last October -- though the $1.20 region has consistently emerged as a floor. What's more, the shares haven't traded near $4.50 since 2014.

psti stock daily chart july 31

Nevertheless, Pluristem Therapeutics has been a darling of analysts, with all four in coverage maintaining a "buy" or better rating. Plus, the average 12-month price target stands all the way up at $4. This puts the lagging stock at risk of downgrades and price-target cuts on continued weakness.

 

If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

Schaeffer's Investment Research Master Portfolio Trial
 


 


 
Special Offers from Schaeffer's Trading Partners